Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 280

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 280
---
| At December 31,2024              |     |             | 52,028,145 |     |               | 1,301 |     |                 | 291,463 |

The authorized share capital of GH Research PLC is 40,000,000,000ordinary shares of nominal value $ 0.025each as of December 31, 2024. Dividend Nodividends were declared or paid during the year (2023: $ nil; 2022: $ nil). Reserves Other reserves of $ 5.2million as of December 31, 2024 (2023: $ 4.7million) comprises amounts expensed in the consolidated statement of comprehensive loss in connection with awards made under the Share Option Plan (see note 17, “Share-based compensation”) and fair value movement on marketable securities (see note 10, “Marketable securities”). Foreign currency translation reserve of $ 12.6million as of December 31, 2024 (2023: $ 10.5million) consists of the cumulative currency translation adjustment in respect of GH Research Ireland Limited whose functional currency is euro. The translation adjustments arise from the retranslation of theresults of such operations from the average exchange rate for the year to the exchange rate at the statement of financial position date as well as the retranslation of the subsidiary’s applicable assets and liabilities.

16.Contingencies As of December 31, 2024, there were no material contingencies which required adjustment to or disclosure in the Group’s financial statements (2023: none).

17.Share-based compensation Share Options In June 2021, the Company adopted a share option plan referred to herein as the Share Option Plan under which grants of options are made to eligible participants. The Company initially reserved 1,202,734ordinary shares for future issuance under the Share Option Plan, which includes ordinary shares pursuant to share-based equity awards issued to date. As of December 31, 2024, the total number of ordinary shares which may be issued under the Share Option Plan was 2,202,704and the Company has 325,861ordinary shares available for the future issuance of share-based equity awards (2023: 404,718shares, 2022: 741,138shares). Under the Share Option Plan,the options may be settled only in ordinary shares of the Company. Therefore, the grants of share options under the Share Option Plan have been accounted for as equity-settled under IFR